Theravance Biopharma, Inc. (NASDAQ: TBPH)

Theravance Biopharma, Inc., a prominent player in the biopharmaceutical industry, is dedicated to the development and commercialization of medicines that have a significant impact on people's lives. The company's primary business activities revolve around the development and commercialization of pharmaceutical products, largely through partnerships and collaborations.

Theravance Biopharma's revenue generation is primarily through the sale of its products. Its product portfolio includes YUPELRI (revefenacin) inhalation solution, which is approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a once-daily, nebulized long-acting muscarinic antagonist (LAMA) that is administered through a standard jet nebulizer. Another key product is ampreloxetine, an investigational product being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Additionally, the company has an economic interest in TRELEGY, a once-daily, single inhaler triple therapy approved for the long-term maintenance treatment of patients with COPD.

In the competitive landscape of the biopharmaceutical industry, Theravance Biopharma holds a competitive position due to its expertise in respiratory diseases, strong partnerships, and late-stage development programs. Key competitors include GSK plc, AstraZeneca plc, and Novartis AG, among others. The company's competitive advantages lie in its focus on respiratory diseases, its robust partnerships, and its ongoing late-stage development programs.

Theravance Biopharma's customers include pharmaceutical companies and healthcare organizations. Its products are marketed and sold through a network of distributors, wholesalers, and retailers, and are available in many countries around the world. The company's human capital strategy places a strong emphasis on employee engagement and development. As of December 31, 2023, the company had 99 employees, with 88 based in the US and 11 based in Dublin, Ireland. The company strives to provide a culture of purpose, engagement, and learning, and has a strong value proposition anchored in its Core Values.

In terms of its product portfolio, Theravance Biopharma's brands include YUPELRI, ampreloxetine, and TRELEGY. YUPELRI, a once-daily, nebulized LAMA, has experienced significant sales growth and reached an all-time high in yearly net sales and profitability in 2023. Ampreloxetine, an investigational product for the treatment of nOH in patients with MSA, has completed two pivotal Phase 3 studies and is currently in a new Phase 3 study. TRELEGY, a once-daily, single inhaler triple therapy for the long-term maintenance treatment of patients with COPD, generated global net sales of $2.7 billion in 2023, representing a 28% increase year-over-year. The product is expected to generate peak sales of $3.7 billion in 2027, according to consensus estimates.